8MM Meningococcal Vaccine Market Value to Reach USD 1.8 Bn in 2025, States GlobalData in Its Report Published at MarketPublishers.com
28 Sep 2016 • by Natalie Aster
LONDON – The market for meningococcal vaccines across the 8MM including Japan, 5EU, the US and Brazil is forecast to gain traction, with its value increasing from around USD 1.1 billion in 2015 to USD 1.8 billion in 2025, at 5.4% a CAGR. This growth will likely be fuelled by the emergence of supplementary meningococcal vaccines in the national routine vaccination schedules for infants and adolescents in some 5EU countries. Further growth is projected to be driven by the launch of a novel pentavalent MenABCWY vaccine in the foreseeable future, whilst the Brazil’s and Japan’s commercial meningococcal vaccine sectors are projected to witness a negative CAGR of 1.8% and 0.9%, respectively.
With the majority of the nations in the 8MM using serogroup B meningococcal vaccines only for patients at increased risk of catching meningococcal disease, the application of these protein-based vaccines on a routine basis is considered as the key unmet need to be addressed in the offing.
The opportunities are expected to be focused on the enhancement of long-term efficacy of a vaccine whilst dealing the cost effectiveness issues formulated by various governmental institutions.
In-demand research report “PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025” created by GlobalData gives an exhaustive assessment of the meningococcal vaccine marketplace across the 8MM.
The study gives an overview of disease, including epidemiology, pathophysiology, etiology, serogroup distribution region-wise, and also gives current routine meningococcal vaccine recommendations of all 8MM in question. The report provides top-line meningococcal vaccine market revenue, from 2015 plus forecasts to 2025, with the latest acquisitions, approvals and government recommendations projected as well. The publication examines a slew of burning issues like strategic competitor assessment, market characterisation, R&D strategies, unmet needs, and clinical research design with respect to the meningococcal vaccine market. It presents a comprehensive pipeline analysis covering exhaustive data breakdown across various phases, emerging new trends under development, brief reviews of innovative projects in early stage development, and an extensive examination of late-stage pipeline products. Furthermore, the report casts light on the competitive landscape in the global meningococcal vaccine market space as well as reviews the performance of major competitors and identifies emerging players with potentially strong product portfolios. An insightful discussion of the key industry restraints, drivers and challenges is provided in the study, with each trend carefully explored to give a qualitative assessment of its implications.
More comprehensive reports by the publisher can be found at GlobalData page.